Plain-English translation of NCT07539415 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase 1 trial testing a new medication called that is being developed to help treat obesity and type 2 diabetes. Researchers want to make sure the medication is safe and understand how your body absorbs and processes it. This is the earliest stage of human testing, conducted in healthy volunteers.
Before a new medication can be given to patients with obesity or diabetes, scientists need to test it first in healthy people to confirm it is safe and to learn how the body handles it. This early-stage safety testing is an essential step before moving forward with larger studies in people with these conditions.
You likely qualify if…
You likely don't qualify if…
As a participant, you would visit the research clinic multiple times to receive the medication and have your safety monitored through blood tests, heart monitoring, and physical exams. The study involves taking different doses of the medication and comparing how your body handles them. The exact duration and number of visits will depend on which study group you are assigned to, but researchers will explain the full schedule during screening.
AI-generated summary from trial data · Aug 3, 2026 · Not medical advice
South Korea
Phase
Safety & dosing
Sponsor
Daewoong Pharmaceutical Co. LTD.
Enrollment target
~72 participants
Started
May 2026
Primary completion
October 2026
Age range
19 Years – 64 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
YeaRa Kwak
Daewoong Pharmaceutical Co. LTD.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.